(NBIX) Neurocrine Biosciences, Inc. SWOT Analysis Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(NBIX) Neurocrine Biosciences, Inc. Complete Analysis Pack
Dive Deeper Into the Research Trail Behind the Analysis
This Neurocrine Biosciences, Inc. SWOT Analysis helps you quickly assess the company’s strengths, weaknesses, opportunities, and threats in a concise, structured format; the page already shows a real preview/sample so you can judge style and substance before buying—purchase the full version to receive the complete ready-to-use analysis.
Strengths
INGREZZA flagship product
INGREZZA is Neurocrine Biosciences’ core commercial asset and a VMAT2 inhibitor approved for tardive dyskinesia and Huntington’s disease chorea. In 2024, INGREZZA delivered about $1.9 billion in net product sales, giving Neurocrine Biosciences a large, recurring revenue base. Its scale also strengthens payer access, physician familiarity, and brand recognition in the neuroscience market.
Four marketed therapies
Neurocrine Biosciences markets four therapies: INGREZZA, ONGENTYS, ORILISSA, and ORIAHNN. That portfolio spans movement disorders, Parkinson’s disease, endometriosis, and uterine fibroids, so Company Name is not tied to one disease area. Multiple approved drugs also widen the addressable market and lower reliance on a single product.
Broad clinical pipeline
Neurocrine Biosciences has five named pipeline assets in development: NBI-921352, NBI-827104, NBI-1065845, NBI-1065846, and NBI-118568. They span epilepsy, essential tremor, major depressive disorder, anhedonia, and schizophrenia, giving the Company exposure to five large, high-unmet-need markets. That breadth gives Neurocrine multiple shots at future growth, even if one program slips.
Specialty neuroscience focus
Neurocrine Biosciences, Inc. stays focused on 3 hard areas: neurological, endocrine, and psychiatric disease. That narrow scope builds deep scientific know-how and helps it run complex CNS trials with more precision. Its specialty model also supports faster decisions in a field where trial failure risk is high.
- 3 core disease areas
- Deep CNS expertise
- Stronger trial execution
Multiple strategic partners
Neurocrine Biosciences, Inc. has 8 named strategic partners, including Heptares Therapeutics, Takeda, Idorsia, Xenon, Voyager, BIAL, Mitsubishi Tanabe, and AbbVie. That network broadens discovery, development, and commercialization reach without forcing the Company to build every asset in-house. It also diversifies innovation sources and can lower execution risk.
- 8 partners widen pipeline access
- Shared work cuts internal burden
- Multiple channels support launches
INGREZZA Drives Neurocrine’s Strong, Diversified Growth Engine
Neurocrine Biosciences, Inc.’s biggest strength is INGREZZA, which produced about $1.9 billion in net product sales in 2024 and anchors a recurring revenue base. Neurocrine Biosciences, Inc. also has four marketed drugs and five named pipeline assets, so growth is not tied to one program. Its focus on neurological, endocrine, and psychiatric disease supports deep CNS expertise, while eight partners help widen reach and cut execution risk.
| Strength | Key data |
|---|---|
| INGREZZA scale | ~$1.9B sales, 2024 |
| Commercial breadth | 4 marketed therapies |
| Pipeline depth | 5 named assets |
| Partner network | 8 strategic partners |
What is included in the product
Detailed Word Document
Analyzes Neurocrine Biosciences, Inc.’s strengths, weaknesses, opportunities, and threats to assess its strategic position.
Editable Excel File
Provides a quick SWOT snapshot for Neurocrine Biosciences, Inc. to simplify strategic decision-making.
Reference Sources
Lists primary, reputable sources for Neurocrine Biosciences to validate market, pricing, and competitive assumptions for fast, traceable decision-making.
Weaknesses
INGREZZA concentration risk
Neurocrine Biosciences, Inc. is still highly tied to INGREZZA: the drug drove about $2.0 billion of roughly $2.4 billion in 2024 revenue, or near 83%. If payers push back, rivals gain share, or safety concerns emerge, the whole growth story weakens fast. A single asset with that much value makes earnings and valuation more exposed.
Limited approved portfolio size
Neurocrine Biosciences, Inc. has only four marketed products, a narrow base for a biopharma company. That leaves less revenue spread than larger peers and makes results more exposed to one product or one label change. Growth still depends heavily on a few launches and lifecycle moves, so any slip can hit sales fast.
Pipeline still clinical stage
Neurocrine Biosciences, Inc. still has several key programs in clinical development, so future growth depends on trials that can fail or slip. Clinical-stage assets carry high attrition risk, and FDA approval is never guaranteed. That makes any delay in late-stage readouts a direct threat to 2025/2026 growth expectations.
CNS development complexity
Neurocrine Biosciences, Inc. faces high CNS development complexity because psychiatric and neurological trials often show variable outcomes, long follow-up, and hard-to-measure endpoints, which can delay readouts and lift failure risk. This makes R&D spend less predictable and can widen execution risk across programs like movement and mood disorders.
- Variable CNS trial outcomes
- Long timelines, complex endpoints
- Higher R&D uncertainty
That matters because one delayed or weak study can slow pipeline value creation and pressure capital allocation.
Exposure to specialty pricing pressure
Neurocrine Biosciences, Inc. is heavily tied to specialty drugs, with INGREZZA driving most of its $2.36 billion 2024 revenue. Specialty therapies often face prior authorization, step edits, and tight formulary control, so even strong clinical data can still mean slower uptake and more rebate pressure. That makes growth more exposed to payer decisions than to demand alone.
- High specialty mix increases payer scrutiny
- Access limits can slow new starts
- Rebates can compress net pricing
Neurocrine’s Growth Hangs on One Drug, One Trial, One Payer
Neurocrine Biosciences, Inc. remains highly dependent on INGREZZA, which generated about $2.0 billion of its roughly $2.4 billion 2024 revenue, so payer pressure or label issues could hit earnings fast. Its four marketed products give it a narrow revenue base, and CNS trials stay risky because outcomes are variable and endpoints are hard to measure. That makes 2025/2026 growth more exposed to one asset, one trial, and one payer decision.
| Weakness | Data point |
|---|---|
| INGREZZA concentration | About 83% of 2024 revenue |
| Narrow portfolio | 4 marketed products |
| Pipeline risk | Clinical-stage assets still unproven |
Preview the Actual Deliverable
Neurocrine Biosciences, Inc. Reference Sources
This is a real excerpt from the complete Neurocrine Biosciences SWOT analysis you'll receive upon purchase—professional, structured, and ready to use; buy now to unlock the full, editable report.
Opportunities
Epilepsy pipeline expansion
NBI-921352 and NBI-827104 give Neurocrine Biosciences, Inc. two shots at epilepsy, a chronic market that affects about 50 million people worldwide and still has major unmet need. If late-stage data stay positive, the company could add new specialty revenue beyond Ingrezza and broaden its neurology base.
Mood disorder programs
NBI-1065845 and NBI-1065846 could tap a U.S. major depressive disorder market that affects about 21 million adults each year, with anhedonia still poorly treated. Psychiatry’s unmet need stays high despite more than 30 antidepressants on the market, so a new mechanism can stand out if data are strong. Neurocrine Biosciences, Inc. could gain pricing and share upside if these assets show clear benefit.
Schizophrenia candidate progress
NBI-118568 could open a large schizophrenia market, a disorder affecting about 24 million people worldwide and often left only partly controlled by current antipsychotics. If Neurocrine Biosciences, Inc. shows clear clinical benefit, it could add a second CNS growth engine beyond its $2.4 billion 2024 revenue base. That would raise the long-term value of the pipeline, but the upside still depends on trial success and safety.
Women’s health growth
ORILISSA and ORIAHNN gave Neurocrine Biosciences, Inc. a women’s health base, with FY2025 net product sales of about $522 million for ORILISSA and $183 million for ORIAHNN. If uptake stays strong, and label expansion or lifecycle moves follow, this segment can grow beyond a niche add-on. Endometriosis affects about 1 in 10 women of reproductive age, and uterine fibroids affect up to 80% by age 50.
- ORILISSA: about $522M FY2025 sales
- ORIAHNN: about $183M FY2025 sales
- Large untreated women’s health pools
Partnered innovation pipeline
Neurocrine Biosciences can use its partnered innovation pipeline to pull in external science and new assets, which lowers dependence on internal discovery alone. In FY2025, the Company had about $2.4 billion in revenue and near $0.5 billion in annual R&D spend, giving it room to fund co-development and licensing talks. That mix can speed new programs and open adjacent areas like neuroscience and rare disease.
External partners add fresh assets.
R&D scale supports faster development.
Deals can extend into new therapies.
Neurocrine's 5-Asset Pipeline Drives $2.4B Revenue
NBI-921352, NBI-827104, NBI-1065845, NBI-1065846, and NBI-118568 give Neurocrine Biosciences, Inc. several shots at large CNS markets, while ORILISSA and ORIAHNN add women’s health scale. FY2025 net product sales were about $522 million for ORILISSA and $183 million for ORIAHNN, and FY2025 revenue was about $2.4 billion.
| Opportunities | FY2025 data |
|---|---|
| Women’s health | $705M sales |
| Core revenue | $2.4B |
| Pipeline | 5 key assets |
Threats
Patent and exclusivity erosion
Neurocrine Biosciences, Inc. leans heavily on branded products, led by INGREZZA, which generated about $2.0 billion of 2024 net product sales. If patent coverage weakens or exclusivity ends, generic or follow-on entrants can cut prices fast and compress margins. That makes patent litigation and loss of exclusivity a material threat to long-term earnings.
Clinical trial failure risk
Neurocrine Biosciences, Inc. faces sharp clinical trial risk because several CNS and psychiatry assets are still unproven in mid- and late-stage studies. A negative efficacy or safety readout can wipe out expected future revenue, leaving the company even more dependent on INGREZZA, its main growth driver. In high-fail-rate CNS trials, one setback can derail years of R&D spend.
Competitive pressure in CNS
Neurocrine Biosciences, Inc. faces heavy pressure in crowded CNS markets, where larger rivals can outspend it on R&D, sales, and payer access. In 2024, Neurocrine Biosciences, Inc. posted $2.36 billion in net product sales, but competing therapies for mood, movement, and psychiatric disorders can still cap share gains. If new drugs show better efficacy, safety, or convenience, uptake of both current and future products may slow.
Regulatory and safety scrutiny
Neurocrine Biosciences, Inc. depends on CNS and endocrine drugs that sit under tight FDA review, so any new safety signal, boxed warning, or label limit could quickly cut prescribing. That risk matters because Ingrezza still drives most revenue, with 2025 sales above $2 billion, so even a small label hit could move results. Pipeline readouts can also slip if regulators ask for more data or trials.
- High safety scrutiny can curb use
- Label changes can reduce sales fast
- Regulatory delays can slow pipeline
Payer and pricing pressure
U.S. and global payers are still pushing lower drug costs, and Neurocrine Biosciences, Inc.'s specialty medicines face tighter prior auth and step-edits. The 2025 Medicare Part D redesign also caps patient out-of-pocket drug costs at $2,000, which can shift more pressure onto manufacturers and plans. That can slow volume growth and squeeze gross margin if rebates rise.
- Higher prior authorization risk
- More rebate and discount pressure
- Slower growth if access tightens
- Margin risk from pricing cuts
Neurocrine’s INGREZZA Dependence Puts Revenue at Risk
Neurocrine Biosciences, Inc. is exposed to INGREZZA concentration risk, with 2024 net product sales of $2.36 billion and 2025 sales above $2 billion. Any patent loss, generic entry, or label change could hit revenue fast. Its CNS pipeline also carries high trial and FDA risk, while payer pressure can raise rebates and slow uptake.
| Threat | Why it matters |
|---|---|
| INGREZZA reliance | $2.36B 2024 sales |
| Pipeline failure | High CNS trial risk |
| Payer pressure | More rebates, slower growth |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.